Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 74Carcinoma, Non-Small-Cell Lung 73Breast Neoplasms 39Lung Neoplasms 31Urinary Bladder Neoplasms 28Nasopharyngeal Carcinoma 28Ovarian Neoplasms 25Neoplasm Metastasis 21Cholangiocarcinoma 18Triple Negative Breast Neoplasms 16Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Gallbladder Neoplasms 13Biliary Tract Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Carcinoma, Transitional Cell 12Nasopharyngeal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 9Lymphoma 7Carcinoma 7Bile Duct Neoplasms 7Lymphoma, Non-Hodgkin 6Adenocarcinoma 6Carcinoma, Hepatocellular 5Adenocarcinoma of Lung 5Neoplasms by Site 4Urothelial Cancer 3

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma, Mucinous × Gemcitabine × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡